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Abstract 17 
The mucus layer is believed to play a part in drug permeation across the oral mucosa. Human freeze-18 
dried saliva (HFDS) and porcine gastric mucin (PGM) was evaluated as model for mucus layer per 19 
se or in conjunction with in vitro and ex vivo buccal permeability models.  20 
Four small molecules (nicotine, mannitol, propranolol, caffeine) showed decreased permeability 21 
across mucin dispersions, compared to controls, and a greater effect was seen with HFDS than with 22 
PGM. Permeability of propranolol and caffeine across filter-grown TR146 cells was decreased by the 23 
presence of mucin, whereas no effect was found on nicotine and mannitol. Incubation of porcine 24 
buccal mucosa with mucin dispersions for 24 h compromised the integrity of the tissue, whereas 30 25 
min incubation did not affect tissue integrity. Tissue incubation with mucin dispersions did not 26 
decrease nicotine permeability. For the studied model drugs, it is concluded that mucin dispersions 27 
constitute a minor barrier for drug diffusion compared to the epithelium. 28 
Keywords 29 
Mucus, permeability, barrier, buccal drug delivery, drug diffusion, absorption, small molecules    30 
31 
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Abbreviations 32 
BSA Bovine serum albumin 33 
HBSS Hanks’ balanced salt solution 34 
HFDS Human freeze-dried saliva 35 
Log P Logarithm of partition coefficient 36 
Log D Logarithm of distribution coefficient 37 
MW Molecular weight 38 
Papp Apparent permeability coefficient 39 
PBS Phosphate buffered saline 40 
PGM Porcine gastric mucin 41 
SD Standard deviation 42 
TEER Transepithelial electrical resistance  43 
4 
 
1 Introduction 44 
Over the last years the interest in oromucosal drug delivery has increased due to advantages with this 45 
administration route. The harsh environment of the gastrointestinal tract is avoided and hepatic first 46 
pass metabolism is circumvented. Furthermore, the oral cavity is easily accessible for rapid self-47 
administration and the formulation can quickly be removed in case of adverse events [1]. The 48 
epithelial surface of a mucosal membrane is covered by a mucus layer. The mucus layer has multiple 49 
physiological functions such as lubrication, hydration, and tissue protection. Mucus is a complex 50 
viscoelastic network, mainly consisting of water (95-99%) and mucins (1-5%) [2]. Mucins are 51 
glycoproteins which may be susceptible to changes in salt concentration or temperature, which can 52 
affect the mucin network and thereby the barrier properties of the mucus layer. It is believed that drug 53 
permeation through the mucus layer is affected by interactions and entanglement with the mucin 54 
network and by the unstirred water layer that mucus constitutes [3-5]. Mucus could retard drug 55 
diffusion by interacting with the drug and by decreasing diffusion rate due to higher viscosity. 56 
Reversely, mucus may increase solubility of the drug, and consequently increase the drug 57 
concentration adjacent to the epithelium.  58 
Only few oromucosal formulations are on the market, and this may be due to lack of standardized in 59 
vitro methods to evaluate and optimize drug delivery systems [6]. Several models for assessing drug 60 
permeability through oral mucosa are known, however, they lack the mucus layer. Permeability 61 
across excised mucosal tissue can be studied in side-by-side diffusion cells such as modified Ussing 62 
chambers or Franz cells [7]. To the authors’ knowledge it has not been confirmed that the mucus layer 63 
on the epithelium is intact after handling the excised tissue [8]. Filter grown cell cultures, such as 64 
TR146 cells derived from human buccal carcinoma have also been used to model oral mucosa [9, 65 
10]. However, these cells do not produce mucus. Cell cultures that produce a mucus layer, such as 66 
HT29-MTX cells derived from human colon adenocarcinoma, form a single cell layer, and thus are 67 
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not suitable for modeling the oral mucosa, consisting of multiple cell layers [11]. Setups for studying 68 
drug transport across a mucus layer have previously been designed for Ussing chambers [12, 13]. 69 
However, they are either not suitable for liquid mucus or require several preparation steps for each 70 
replicate. Thus, there is a need for a simple setup containing mucus that can be used for high 71 
throughput studies.  72 
Mucin can be obtained from mucus collected by gentle scraping of a mucosal membrane, from saliva, 73 
or from gastric fluid in animals or humans. Porcine gastric mucin (PGM) is commercially available 74 
as a crude mixture of mucin. Despite the gastric origin, PGM is commonly used to mimic mucus in 75 
the oral cavity [14, 15]. However, PGM may differ significantly from mucin found in the human 76 
saliva and on the oral mucosa, due to the difference in species and place of origin [16]. Furthermore, 77 
PGM has been through processing steps that may alter the properties of the molecules, thus there may 78 
be a need for a mucin source that is more similar to native oromucosal mucus. 79 
Currently, oromucosal drug delivery is more feasible for small molecules, since they can diffuse the 80 
epithelial cell layers more easily than larger molecules. Therefore, four small molecules with different 81 
physicochemical properties were chosen as model drugs for this study; nicotine (MW = 162.2 g/mol; 82 
log D6.8 = 0.30, calculated from log P = 1.43 and pKa = 7.9) [17], mannitol (MW = 182.2 g/mol; log 83 
P = -3.1) [18], propranolol (MW = 259.3 g/mol; log D6.8 = 1.20) [19], and caffeine (MW = 194.2 84 
g/mol; log P = -0.07) [20]. 85 
The aim of this study was to implement a mucin dispersion mimicking the mucus layer into in vitro 86 
and ex vivo permeability models and study the barrier properties of the mucin dispersion using small 87 
molecules. Thus, the permeability of nicotine, mannitol, propranolol and caffeine across a mucin 88 
dispersion, TR146 cells and porcine buccal mucosa was studied. The TR146 cells and the porcine 89 
buccal mucosa were incubated with mucin dispersions prior to the permeability experiments. 90 
Furthermore, the suitability of PGM and human freeze-dried saliva (HFDS) as sources of mucin was 91 
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evaluated. Implementation of a mucus layer will improve the predictability of the currently used 92 
permeability models, and this has to the authors’ knowledge not previously been done. 93 
2 Materials and methods 94 
2.1 Materials 95 
Potassium dihydrogen phosphate, calcium chloride, sodium hydrogen carbonate, sodium chloride and 96 
ortho-Phosphoric acid 85% were purchased from Merck KGaA (Darmstadt, Germany). Sodium 97 
phosphate monobasic anhydrous was obtained from Amresco (Solon, OH, USA). Potassium chloride 98 
was obtained from Riede-de Haën (Seelze, Germany). Hanks’ balanced salt solution (HBSS) (10x), 99 
+CaCl2, +MgCl2 and 7.5% sodium bicarbonate was purchased from Gibco® life technologies (Grand 100 
Island, NY, USA). Nicotine bitartrat dihydrate was kindly donated from Fertin Pharma (Vejle, 101 
Denmark). Pearlitol® 160 (mannitol) was obtained from Roqette Pharma (Lestrem, France). Caffeine 102 
was purchased from VWR (Leuven, Belgium). [14C]-mannitol (57.1 mCi/mmol), [3H]-nicotine (80.4 103 
Ci/mmol), [14C]-caffeine (54.9 mCi/mmol), [3H]-propranolol (18.6 Ci/mmol) and Ultima GoldTM 104 
liquid scintillation fluid were purchased from Perkin Elmer Inc. (Waltham, USA). Falcon 12-well 105 
tissue culture plates and cell culture inserts (polyethylene terephthalate membrane, 0.9cm2 area, 0.4 106 
mm pore size) were obtained from Becton Dickinson Labware (Franklin Lakes, NJ, USA). Bovine 107 
serum albumin (BSA), Mucin from porcine stomach, type II (PGM), (±)-propranolol hydrochloride, 108 
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), Alcian blue 8GX, MTS-4-fluroescein, 109 
phenazine methosulfate and silicone oil were all purchased from Sigma-Aldrich (St. Louis, MO, 110 
USA). Human freeze-dried saliva (HFDS) from pooled saliva samples (dialyzed and free of minerals) 111 
was kindly donated by the Department of Odontology, University of Copenhagen (Copenhagen, 112 
Denmark). The saliva was centrifuged at 2000 g for 10 min, dialyzed at 5°C for two days and finally 113 
lyophilized. Dialysis tubing visking, cellulose, type 36/32 inch, thickness 0.02 mm, width 44 mm, 114 
MWCO 14,000 was from Carl Roth GmbH + Co. KG (Karlsruhe, Germany). Deionized water was 115 
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collected from Milli-Q water system, SG Ultra Clear 2002 from Evoqua Water Technologies LLC 116 
(Warrendale, PA, USA).  117 
2.2. Methods 118 
2.2.1 Preparation of mucin dispersions 119 
A buffer, named saliva buffer, containing 5 mM KH2PO4, 15 mM KCl, 1 mM CaCl2 and 5 mM 120 
NaHCO3 was prepared and adjusted to pH 6.8 [21]. PGM and HFDS were dispersed in saliva buffer 121 
and exposed to slow stirring at 5°C overnight. The concentrations of mucin varied in the experiments 122 
and are stated in the respective sections below. 123 
2.2.2 Comparison of mucin sources 124 
The mucin sources, PGM and HFDS, were visually compared in dry solid form. Furthermore, the pH 125 
of the two dispersions was measured. The viscosity of PGM and HFDS dispersions (2% w/v) were 126 
determined as described by [22]. Briefly, an AR-G2 plate and cone rheometer (TA instruments-127 
Waters, New Castle, USA) was used with a 40 mm aluminum steel plate in diameter. A gap of 500 128 
µm was selected (630 µL sample) and all the measurements were conducted at 37 °C. A protective 129 
casing, custom made at the Department of Pharmacy, University of Copenhagen (Denmark) was 130 
attached to the fixed heating plate and silicone oil (500 µL) was placed around the sample to prevent 131 
evaporation. The sample was equilibrated for 5 min before measurements were conducted. A steady 132 
state flow test to determine the viscosity was performed (shear rates 0.001-1000 s-1, three consecutive 133 
measurements of 10 s with <5% variance). Four measurements were conducted per decade within a 134 
maximum time for each shear rate of 2 min (discarded if equilibrium was not reached within 2 min). 135 
TA Instruments Rheology Advantage Software (TA Instruments-Waters) was used to generate 136 
rheology data.  137 
2.3 Permeability studies 138 
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2.3.1 Permeability across an isolated mucin dispersion 139 
The new permeability device consisting of a test sample compartment in a tailor-made slider was 140 
developed for the modified Ussing chambers (Physiologic Instruments Inc., San Diego, CA, USA) to 141 
enable drug permeation study through e.g. an isolated mucus layer. 142 
The new permeability device consists of three parts as shown in Fig. 1; a cylinder placed between a 143 
two piece slider. Dialysis membranes were rinsed in cold water and then soaked three times 5 min in 144 
200 mL 100 °C hot water. The prepared dialysis membranes were placed between the slider and the 145 
cylinder (positions shown with A in Fig. 1) and held in place by joining the parts. The mucus 146 
dispersion was then added with a syringe through a small hole in the slider and cylinder. The diffusion 147 
area was 0.50 cm2 and the thickness of the mucin layer (cylinder length) was 6.0 mm. The 148 
composition of the receptor and donor fluid is given in Table 1. The permeability of nicotine, 149 
mannitol, propranolol and caffeine was studied across saliva buffer, 2% (w/v) PGM dispersion or 2% 150 
(w/v) HFDS dispersion. 151 
The study was conducted in modified Ussing chambers as previously described by Holm et al. [23]. 152 
Briefly, 2.0 mL of donor and receptor fluid was added to the respective compartments. Stirring was 153 
ensured by supplying hydrated atmospheric air, and the temperature was kept at 36±1°C. Receptor 154 
samples of 100 µL were taken from the receptor compartment at 5, 10, 20 and 30 min and then every 155 
30 min up to 5 h. From the donor compartment, 100 µL was taken in triplicates at the start and end 156 
of the experiment. After sampling the compartments were replenished. At the end of the experiment 157 
a 100 µL sample was taken from the mucin dispersions or saliva buffer. Drug content was determined 158 
in the dialysis membranes by rinsing off excess drug and placing the dialysis membrane in a 159 
scintillation vial for measurement. 160 
 161 
2.3.2 Permeability across TR146 cells 162 
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The TR146 cell line was provided by Imperial Cancer Research Technology (London, UK) and 163 
cultivated and grown on filters as previously described [24]. On the first day of the experiment filter-164 
grown cells aged 25-27 days were washed on the apical side and the growth medium was changed on 165 
the basolateral side. The cells were incubated on the apical side with 200 µL 4% (w/v) PGM or HFDS 166 
dispersion. Cells incubated with saliva buffer were used as a control. The cells were incubated at 167 
37°C in 5% CO2/95% air at 98% humidity for 24 h.  168 
On the second day of experiment, the initial transepithelial electrical resistance (TEER) was measured 169 
on the control cells (Endohm and voltmeter EVOM from World Precision Instruments (Sarasota, FL, 170 
USA)). The composition of donor and receptor fluids is shown in Table 2. 1600 µL receptor medium 171 
was added to the basolateral side and 220 µL donor solution was added to 200 µL mucin dispersion 172 
or saliva buffer on the apical side. The experiment was conducted at 37°C using a thermostatic 173 
horizontal shaker, 100 rpm, (Edmund Bühler, swip Type KL-2) (Hechingen, Germany). 100 µL 174 
samples were taken from the basolateral side at time 10 min, 30 min, 45 min, 60 min and then every 175 
30 min up to 240 min, and the compartment was replenished with receptor fluid. At 10 min a donor 176 
sample of 20 µL and at 240 min three donor samples of 20 µL were taken. The first samples were 177 
taken at 10 min to allow the donor fluid to mix with the mucin dispersion. After the permeability 178 
experiment the cells were washed twice with HBSS buffer on both apical and basolateral side, TEER 179 
was measured and a MTS-PMS viability test was conducted as described by Eirheim et al. [25].  180 
2.3.2.1 Mucin attachment to cell surfaces 181 
After 24 h incubation the mucin dispersions or saliva buffer was gently removed and the cells were 182 
washed in 0.1 M phosphate buffered saline (PBS) pH 6.8. 200 µL Alcian blue solution (1% (v/v) 183 
Alcian blue and 3% (v/v) acetic acid in water) was added to the apical side and the setup was shaken 184 
(100 rpm) for 5 min. The Alcian blue solution was gently removed and the cells were washed twice 185 
in PBS pH 6.8. The cells were than examined under an Olympus BH2 light microscope (Olympus, 186 
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Tokyo, Japan) and representative pictures were taken with an AxioCam ERc5s (Zeiss, Jena, 187 
Germany). 188 
2.3.3 Permeability across porcine buccal mucosa 189 
Porcine buccal mucosa was obtained from healthy experimental control pigs (approx. 30 kg Danish 190 
Landrace/Yorkshire x Durox (D-LY)). Immediately after euthanization of the pigs the cheeks were 191 
excised using a scalpel and placed in ice cold PBS pH 7.4. Within 3 h the excised cheeks were frozen 192 
in 40% (w/v) glycerol and 20% (w/v) sucrose in PBS pH 7.4, and on the day of experiment the tissue 193 
was thawed as described by Marxen et al. [26]. The buccal mucosa was trimmed with surgical scissors 194 
and sliced to a thickness of 792 µm ± 88 µm (n=36) using a Stadie-Riggs tissue slicer (Thomas 195 
Scientific, Swedesboro, NJ, USA). The buccal mucosa was mounted on slider P2405 from 196 
physiologic instruments Inc. (San Diego, CA, USA) (exposed area 0.40 cm2). The sliders were placed 197 
in the upper compartment of a desiccator, the epithelium facing upwards. The lower compartment of 198 
the desiccator was filled with NaCl saturated water to ensure high humidity. 100 µL saliva buffer, 199 
5% (w/v) PGM or HFDS dispersion was added to the apical surface of the tissue and incubated at 37 200 
°C for 24 h, 30 min or the tissue was used immediately. When incubating for 24 h, the sliders were 201 
placed in PBS pH 7.4 to keep the basolateral side of the tissue moist.  202 
The compositions of the donor and receptor solutions are presented in Table 1. The permeability 203 
experiment was conducted as described in Section 2.3.1, with few changes: After the experiment, the 204 
tissue was dissolved in approximately 1.0 mL concentrated phosphoric acid, heated to 70°C and a 205 
100 µL sample was taken for quantification of the radiolabeled model drugs. 206 
 207 
 208 
2.4 Quantitative analysis 209 
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2 mL Ultima GoldTM liquid scintillation fluid was added to all samples before whirl-mixing. 210 
Quantitative analysis of [3H]-nicotine, [14C]-mannitol, [3H]-propranolol and [14C]-caffeine was 211 
performed by liquid scintigraphy using a Tri-Carb 2910TR Liquid Scintillation Analyzer (Perkin 212 
Elmer, Waltham, MA, USA). 213 
2.5 Data analysis 214 
Accumulated amount (Q, mol) of nicotine, mannitol, propranolol and caffeine appearing in the 215 
receptor compartment was plotted as a function of time (t). Steady state flux (JSS, mol s-1 cm-2) was 216 
calculated as the slope of the linear section of this curve (R2 above 0.99 for isolated mucin layer and 217 
porcine buccal mucosa; R2 above 0.95 for TR146 cells), using Equation 1, where A (cm2) is the area 218 
of diffusion. 219 
 𝐽𝐽𝑆𝑆𝑆𝑆 =  𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 ∗ 1𝐴𝐴  Equation 1 220 
Steady state flux was obtained at different time intervals: Isolated mucin layer (90-210 min); porcine 221 
buccal mucosa (90-300 min); TR146 cells (45-150 min for nicotine and caffeine, 120-240 for 222 
propranolol and mannitol).  223 
The apparent permeability coefficient (Papp) was calculated from Fick’s first law of diffusion (JSS = 224 
Papp∙ΔC). When sink conditions are upheld, Fick’s first law can be simplified to Equation 2, under the 225 
assumption that Cdonor >> Creceptor. Thus Papp (cm s-1) was calculated from Equation 2, where C0,donor 226 
(mol cm-3) is the initial donor concentration.  227 
 𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎 = 𝐽𝐽𝑆𝑆𝑆𝑆𝐶𝐶0,𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑     Equation 2 228 
The total recovery (% of initial drug added) of the four model drugs was the sum of the accumulated 229 
drug amount (Q) at the end of the experiment in receptor compartment, donor compartment and drug 230 
amount in isolated mucin dispersion, saliva buffer, or porcine buccal mucosa, respectively.  In the 231 
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cell studies the filter grown TR146 cells were used for viability testing, and thus the drug retained in 232 
cells was not quantified. Due to low recovery of propranolol, an additional experiment was performed 233 
to quantify the amount of propranolol in filter and cells.   234 
2.6 Statistical analysis 235 
Data in this study are presented as means with standard deviations (SD) unless otherwise stated. One-236 
way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test was used to 237 
determine statistically significant difference between three or more means. An unpaired t-test was 238 
used to compare two means. Both tests were performed assuming equal variance and normal 239 
distribution of data. GraphPad Prism 7 for Windows, from GraphPad Software Inc. (La Jolla, CA, 240 
USA) was used for all statistical calculations. P-values below 0.05 were considered statistically 241 
significant. 242 
3 Results and discussion 243 
3.1 Comparison of mucin sources  244 
The mucin sources appeared very different in solid dried forms. PGM is a fine brownish powder 245 
whereas HFDS has a bulky white fibrous structure. The pH of PGM dispersion after stirring overnight 246 
was 4.4 ± 0.3 (n=9) and the pH of HFDS dispersion was 6.6 ± 0.4 (n=9). A t-test showed that the pH 247 
of PGM dispersion was significantly different from pH of the HFDS dispersion, which was expected 248 
since PGM is gastric mucin, and thus originates from an acidic environment, whereas HFDS is 249 
derived from saliva with an average pH of 6.8. In the present studies the mucin dispersions were 250 
adjusted to pH 6.8 to mimic pH in the oral cavity. Mucin contains acidic functional groups, including 251 
sialic acid [27]. Adjusting pH will affect the degree of ionization of the acidic groups, thus a change 252 
in pH will likely affect the interactions between mucin strands, causing enlargement or compaction 253 
of the mucin network. Therefore, it is advantageous to use a mucin-type with an innate pH as close 254 
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to pH 6.8 as possible, thus HFDS would be a more suitable source for mucin used to mimic mucus in 255 
the oral cavity. 256 
The viscosity was determined to compare the shear thinning properties and viscosities of the two 257 
types of mucin dispersion.  258 
 “The viscosity of a mucin dispersion demonstrates the degree of entanglement of mucin, and it is 259 
known that increased viscosity correlates with decreased permeability through the dispersion [28]. 260 
The viscosities as a function of shear rate was determined for a 2% (w/v) PGM dispersion and a 2% 261 
(w/v) HFDS dispersion. The results are presented in Fig. 2. The HFDS dispersion had a higher 262 
viscosity than the PGM dispersion throughout the whole shear rate range (Fig. 2). Furthermore, a 263 
decrease in viscosity with increasing shear rates (shear thinning) was observed for the HFDS 264 
dispersion whereas the PGM dispersion had a constant viscosity at shear rates above 1 s-1. At shear 265 
rates below 1 s-1 several of the measurements on PGM gave negative values and were excluded. It 266 
has been estimated that the movements in the oral cavity during speaking and swallowing correspond 267 
to shear rates of approximately 1-160 s-1 [29, 30]. The rheology measurements of the PGM dispersion 268 
was considered acceptable, since the measurements above 1 s-1 shear rate was consistent, and this is 269 
the range of shear rate of interest in oromucosal drug delivery. It is known that saliva and mucus 270 
exhibit shear thinning properties [29], thus, based on the rheology results presented in Fig. 2 showing 271 
HFDS to exhibit shear thinning unlike PGM, it appeared that HFDS was more similar to native mucus 272 
and saliva. The observed differences may be due to differences between mucin from porcine gastric 273 
fluid and human oral mucin [16]. Before the rheology measurements, pH was adjusted to 6.8, which 274 
may affect protein conformation and interactions [31]. PGM originates from a gastric environment 275 
with pH 1-2, and thus may be more affected by the pH increase compared to HFDS. Furthermore, it 276 
is unknown what processing steps PGM has been subjected to, and the processing may have affected 277 
the mucin molecules in a manner that decreased the gel forming properties. Measures of pH and 278 
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viscosity indicate that the HFDS is a more suitable mucin source than PGM, in terms of mimicking 279 
saliva and the mucus layer in the oral cavity. However, PGM, but not HFDS, is commercially 280 
available.” 281 
 282 
3.2 Permeability studies 283 
3.2.1 Permeability across an isolated mucin dispersion 284 
The Papp was determined for the four model drugs permeating across the 2% (w/v) PGM, 2% (w/v) 285 
HFDS dispersions and the saliva buffer. The results are presented in Fig. 3, and the Papp values are 286 
given in Table 3. The Papp of both nicotine and mannitol across the saliva buffer was significantly 287 
higher than the Papp across the PGM dispersion, which in turn was higher than Papp across the HFDS 288 
dispersion (Fig. 3a and b). The Papp of propranolol across the saliva buffer was significantly higher 289 
than the Papp across the PGM dispersion and the HFDS dispersion. However, no significant difference 290 
was observed between the PGM and the HFDS dispersions (Fig. 3c). For caffeine the Papp across the 291 
saliva buffer and the PGM dispersion was significantly higher than the Papp across the HFDS 292 
dispersion. No significant difference was observed between the PGM dispersion and the saliva buffer 293 
(Fig. 3d).    294 
Overall, it appears that the mucin dispersions act as a barrier to drug diffusion, and that HFDS 295 
constitutes a larger barrier than PGM. The diffusion of a drug is dependent on the molecular size of 296 
the drug and the viscosity of the medium. As described in Section 3.1 the viscosity of HFDS was 297 
higher, especially at low shear rates. The mucin dispersions are unstirred in this setup, thus the 298 
difference in viscosity may be an explanation for the decreased permeability found across HFDS. 299 
However, the mucin dispersions are not simply an unstirred water layer as they contain glycoproteins 300 
that potentially interact with the drug molecule. Several studies have shown the ability of mucin to 301 
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interact with a broad range of molecules [32, 33]. A detailed study of interactions between the model 302 
drugs and mucin is beyond the scope of this study. 303 
The cylinder containing the mucus dispersions or the saliva buffer was 6.0 mm thick. The thickness 304 
of the mucus layer in the oral cavity shows regional variations, and has been determined to be 305 
approximately 50 µm in the buccal area [34]. That is approximately 100 times thinner than in this 306 
setup and it is likely that the permeability differences found will be negligible compared to the barrier 307 
exerted by the epithelium.  308 
3.2.2 Permeability across TR146 cells 309 
The TR146 cells were incubated with 4% (w/v) of PGM, 4% (w/v) HFDS dispersion or saliva buffer 310 
for 24 h, before determining Papp of the four model drugs across the cells.  311 
The results are presented in Fig. 4, and the exact values are given in Table 3. No significant difference 312 
was seen between the Papp of nicotine across the cells incubated with saliva buffer, PGM dispersion 313 
and HFDS dispersion (Fig. 4a). The Papp of mannitol across the PGM dispersion was significantly 314 
lower than Papp across the cells incubated with saliva buffer or the HFDS dispersion. However, no 315 
significant difference was seen between Papp of mannitol across the saliva buffer and HFDS dispersion 316 
(Fig. 4b). The Papp of propranolol and caffeine across the PGM and HFDS dispersion was significantly 317 
lower than the Papp across saliva buffer. However, no significant difference was observed between the 318 
PGM and HFDS dispersions (Fig. 4c and d).  319 
The effects from the mucin dispersion on nicotine permeability across an isolated layer (Section 320 
3.2.1), is not confirmed when the TR146 cells are present, indicating that the cell layers constitute a 321 
larger barrier to nicotine, than the one provided by the mucin dispersions. Also the differences found 322 
between HFDS and PGM dispersions, for propranolol and caffeine disappeared, which indicates that 323 
the effect shown with a 6.0 mm mucin dispersion layer is larger than the barrier exerted by the mucus 324 
layer in vivo. Moreover, the findings indicate that certain interactions between the drug molecules 325 
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and mucin did take place, as nicotine appeared less affected by mucin dispersions than the other 326 
model drugs. Papp for propranolol was decreased by 47% and 58% in the presence of PGM and HFDS 327 
dispersions, respectively, suggesting a higher degree of interaction with propranolol compared to the 328 
other model drugs. In accordance with previous findings we found that mucus constituted an 329 
increasing barrier to drug diffusion with increasing lipophilicity of the diffusing drug [11, 35]. This 330 
substantiates the need of a model as the one presented here, to determine whether the mucins affect 331 
the permeability of a drug molecule of interest.  332 
3.2.2.1 Integrity and viability of TR146 cells 333 
Following the permeability study TEER and MTS/PMS tests were used to determine the integrity and 334 
viability, respectively, of the TR146 cell layers. TEER values are an indication of electron transport 335 
particularly via the paracellular pathway. The initial TEER value of the TR146 cells was determined 336 
to be 145±43 Ω cm2 (n=19) after 24 h incubation with saliva buffer. After the 4 h permeability study, 337 
the TEER value for the TR146 cells incubated with PGM dispersion was 339±100 Ω cm2 (n=13), 338 
with HFDS dispersion was 196±31 Ω cm2 (n=11) and with saliva buffer was 157±59 Ω cm2 (n=14). 339 
The TEER value for PGM incubated cells were significantly higher (p<0.05) than the initial TEER 340 
value, and no significant differences were found between HFDS and buffer incubated cells and the 341 
initial TEER value. The initial TEER value of 145 Ω cm2 indicate that the integrity of the TR146 cells 342 
was maintained after 24 h of incubation with saliva buffer, which is supported by Sander et al. who 343 
reported an initial TEER value of 151±38 Ω cm2 (n=119) on filter-grown TR146 cells. Furthermore, 344 
the integrity of the cell layers is not compromised during the permeability study. The TEER values 345 
were increased for the cells incubated with PGM indicating that incubation with mucin dispersions 346 
decreased electron transport. The findings are in line with Pontier et al. who showed that TEER values 347 
were increased after the HT29-MTX cells had intrinsically produced a mucus layer from mucus 348 
secreting goblet cells [36].  349 
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The integrity of the TR146 cell layers was supported by the relatively low Papp of mannitol. Mannitol 350 
is routinely used as a marker for integrity of the cell layers, in particular the paracellular pathway. 351 
Jacobsen et al. showed that mannitol permeability across TR146 cell layers grown for 30 days was 352 
5.2∙10-6 cm/s, and since the mannitol permeability found in this study was between 1.4 and 3.9∙10-6 353 
cm/s (Table 3), the integrity of the cell layers seems to be maintained [24]. 354 
The MTS/PMS assay measures dehydrogenase activity in cells as a measure of cell viability. The 355 
dehydrogenase activity after a 4 h permeability study in TR146 cells incubated with saliva buffer was 356 
assumed to be 100% viable and the cellular viability of the TR146 cells incubated with PGM and 357 
HFDS dispersions were determined relative to the cells incubated with saliva buffer.  According to 358 
Nielsen and Rassing [37], TR146 cells were not sensitive towards pH changes in the range 5.5-9.0, 359 
or to osmolality changes in the range approximately 100-400 mOsm, thus it was assumed that the 360 
saliva buffer would not affect viability of the TR146 cells. After 24 h incubation with mucin 361 
dispersion and a 4 h permeability study the viability in cells exposed to nicotine and mannitol was 362 
106% ± 4% (PGM) and 102% ± 2% (HFDS), and in cells exposed to propranolol and caffeine the 363 
viability was 107% ± 2% (PGM) and 114% ± 21% (HFDS).  364 
MTS/PMS assays are often used to measure cellular toxicity of drugs. However, in this study it was 365 
mainly used as a measure of the impact of incubation with PGM and HFDS dispersions compared to 366 
saliva buffer (control). The selected concentrations of the model drugs have been validated in 367 
previous studies, thus not expected to be toxic for the TR146 cells [10, 17, 38]. In this study the 368 
viability of the cells did not decrease after exposure to the mucin dispersions, compared to incubation 369 
with saliva buffer. The high integrity and viability supports the feasibility of the in vitro TR146 cell 370 
model to study the effect of mucin on drug permeation. 371 
3.2.2.2 Mucin attachment to cell surfaces 372 
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After incubation with mucin dispersions the attachment of mucin to the TR146 cells was qualitatively 373 
examined by staining the cells with Alcian blue dye. Representative images of the stained cells are 374 
presented in Fig. 5. Alcian blue stains the negatively charged groups in mucin at physiological pH 375 
[39]. 376 
The TR146 cells incubated with saliva buffer (Fig. 5, left) showed scattered blue spots on the cell 377 
layer surface. The staining of the TR146 cells incubated with PGM dispersion resembles the cells 378 
incubated with saliva buffer solution. However, a few more densely stained areas were found on the 379 
cells (Fig. 5, middle). The TR146 cells incubated with HFDS dispersion displayed larger stained areas 380 
(Fig. 5, right). The Alcian blue stained cell surfaces clearly indicated a larger amount of mucin 381 
attached to the cell surface when incubating with the HFDS dispersion. The attachment could be due 382 
to interactions between the cell surface and mucin. The small amount of blue stains present on the 383 
TR146 cells incubated with saliva buffer could indicate lack of washing during the staining procedure 384 
or that other glycoproteins attached to the epithelial cell surface interacts with Alcian blue [40]. 385 
3.2.3 Permeability across porcine buccal mucosa  386 
It was attempted to reintroduce a mucus layer to excised porcine buccal mucosa by incubating the 387 
tissue with 5% (w/v) mucin dispersions. Due to limitations in tissue supply only nicotine and mannitol 388 
were studied.  389 
Initially, the tissue was incubated with saliva buffer or PGM for 24 h to allow time for interactions 390 
between cell-bound mucin and mucin from the dispersions. The studies of mannitol (Fig. 6, b) 391 
indicated that the integrity of the porcine buccal mucosa was compromised after 24 h incubation 392 
compared to non-incubated tissue, for which mannitol amount was below the quantification limit (10x 393 
noise/background). The lost integrity after 24 h incubation could be ascribed to hydration of the tissue, 394 
which was further implied by visual swelling of the tissue after 24 h incubation and the permeability 395 
study [41].  396 
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Secondly, porcine buccal mucosa was incubated for only 30 min with mucin dispersions or saliva 397 
buffer. The choice of 30 min was based on previous studies allowing buccal mucosa to equilibrate 398 
for 30 min, prior to the experiment [42]. As expected, after 30 min incubation with PGM, HFDS or 399 
saliva buffer the permeated amount of mannitol was below the quantification limit (Fig.  6b), 400 
indicating that tissue integrity was not compromised. Accordingly, the effect of mucin dispersions on 401 
mannitol permeability across buccal mucosa cannot be determined. 402 
The Papp values of nicotine after different incubation times were not affected by the possible loss of 403 
tissue integrity, hence the Papp values of nicotine after 24 h incubation was not significantly higher 404 
than Papp for non-incubated tissue (Fig. 6a). The Papp of nicotine after incubation for 30 min in PGM 405 
dispersion was significantly higher than the Papp found with no incubation, 24 h in both saliva buffer 406 
and PGM dispersion and after 30 min in HFDS dispersion. No significant difference was observed 407 
between any of the other treatments. The significantly higher Papp value after incubation for 30 min 408 
in PGM dispersion could indicate an enhancing effect on nicotine permeability. However, since none 409 
of the findings from Section 3.2.1 and 3.2.2 indicate an enhancing effect of the PGM dispersion this 410 
is believed to be coincidental. 411 
Nicotine is more lipophilic than mannitol and permeates through both the transcellular pathway and 412 
the paracellular pathway [43]. At pH 6.8, 93% of the nicotine will be mono-protonated. However, the 413 
non-ionized form passing via the transcellular pathway contributes more to the apparent permeability 414 
of nicotine than the mono-protonated form following the paracellular pathway [17, 43]. As a result, 415 
the possible decrease in barrier integrity for mannitol has insignificant effect on the permeation of 416 
nicotine, as it predominantly follows the transcellular pathway. 417 
In Section 3.2.1 and Fig. 3 it is shown that PGM and HFDS decreases drug permeation across an 418 
isolated mucin dispersion. This finding was not supported from the results with porcine buccal 419 
mucosa. Except for 30 min incubation with PGM dispersion, which increased nicotine permeability, 420 
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no other treatments significantly affected the permeability of nicotine compared to the permeability 421 
across non-incubated tissue. This could be explained by lack of interactions between the tissue and 422 
the applied mucin. The extent of interaction could be decreased by damage of the mucosal surface 423 
from handling, such as freezing, thawing and slicing of the tissue. Bio-incompatibility between the 424 
tissue and the applied mucin could also affect the degree of interaction. Another possible explanation 425 
for the lack of effect on nicotine permeability could be that the epithelium constitutes a much larger 426 
barrier to nicotine, hence a possible effect from the mucin dispersions become negligible in 427 
comparison.     428 
3.2.4 Total drug recovery 429 
After the permeability studies the total recovery of the four model drugs was determined. The results 430 
are presented in Table 4. For nicotine, mannitol and caffeine the recoveries were acceptable, whereas, 431 
the recovery of propranolol was lower. 432 
The relatively poor recovery for propranolol is likely due to adsorption to the Ussing chamber walls 433 
and cell inserts. It has previously been shown that diazepam, a lipophilic small molecule, adsorbed to 434 
Ussing chamber walls during transport studies [44]. In the cell studies the recovery was initially 435 
measured without adding propranolol content in the filter-grown cells, as these were used in viability 436 
testing; however, the recovery of propranolol was only 56.5% (Table 4). Therefore, an additional 437 
experiment with propranolol was performed, where the propranolol content of the filter and cells was 438 
added to the recovery resulting in a propranolol recovery of 91.4% (Table 4). It is likely that 439 
propranolol, due to its lipophilic nature, was mostly located in the lipophilic cell layers. Other studies 440 
have also shown that approximately 30% of propranolol was located in filter-grown TR146 cells after 441 
a permeability study [24]. 442 
4 Conclusions  443 
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The pH of the HFDS dispersion and its shear thinning properties is more similar to native oral mucus 444 
than PGM, thus HFDS is more suitable for mimicking the mucus layer in the oral cavity.  445 
A new one compartment device has been applied to study drug permeability across an isolated mucin 446 
dispersion or saliva buffer. Four model drugs showed decreased permeability across mucin 447 
dispersions and a greater effect was seen with HFDS than with PGM. The effect on drug permeation 448 
could be caused by differences in viscosity between the mucin dispersions and the saliva buffer or by 449 
interactions between drug molecules and mucin. 450 
TR146 cells were subjected to mucin dispersions 24 h prior to a permeability study. This model may 451 
become a promising in vitro method to study drug permeation across a mucus layer in conjunction 452 
with a multi-layered epithelium. The integrity and viability of the TR146 cells were maintained during 453 
24 h incubation and a subsequent permeability study. Permeability of propranolol and caffeine was 454 
decreased by the presence of mucin, however, this was not shown for nicotine and mannitol. The 455 
HFDS attached to the TR146 cell surface to a higher extent than PGM, however, the strength and 456 
mechanism behind the attachment needs further studies.  457 
Incubation of porcine buccal mucosa with mucin dispersions for 24 h caused compromised integrity 458 
of the tissue. Mannitol permeability across non-incubated tissue and tissue incubated for 30 min was 459 
too low to be quantified. Tissue incubation with mucin dispersions did not decrease nicotine 460 
permeability, indicating that the epithelium constitute the main barrier for nicotine diffusion across 461 
porcine buccal mucosa. Further studies are needed to determine whether it is possible to reintroduce 462 
mucin molecules on the tissue surface. 463 
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